Focused Ultrasound Drug Delivery — PatSnap Eureka
Focused Ultrasound Drug Delivery: BBB Opening & Brain Tumor Pipeline
Focused ultrasound (FUS) has emerged as a transformative noninvasive platform for overcoming the blood-brain barrier, enabling targeted delivery of chemotherapeutics, biologics, nanoparticles, and gene vectors to the CNS with millimeter-scale spatial precision — backed by FDA-cleared hardware and active Phase I clinical trials.
Why the Blood-Brain Barrier Is the Central Challenge in CNS Pharmacotherapy
The blood-brain barrier (BBB) prevents passage of greater than 98% of systemically administered pharmaceutical agents. Its impermeability stems from tight junctions connecting adjacent endothelial cells — including claudins and occludins — highly selective transporter systems, and low transcytotic activity. This makes systemic delivery of chemotherapeutics, biologics, and gene vectors to the CNS fundamentally ineffective without an active disruption strategy.
In the tumor context, retrieved results distinguish between the intact BBB in surrounding normal brain parenchyma and the structurally altered blood-tumor barrier (BTB) within malignant tissue. Despite vascular leakiness in glioblastoma multiforme (GBM), the BTB paradoxically maintains drug exclusion through elevated interstitial fluid pressure and nanoporous electrostatically charged tissue — meaning even tumors with compromised vasculature resist pharmacological penetration.
Beyond oncology, the same barrier constrains treatment of neurodegenerative diseases. Tau protein aggregates and amyloid-beta (Aβ) targeted in Alzheimer's disease, GDNF delivery for Parkinson's disease, and neuroimmune pathway modulation all require a strategy to transiently open the BBB with spatial precision — the exact capability focused ultrasound now provides.
According to WHO data, neurological disorders are among the leading causes of disability globally, underscoring the urgency of developing effective CNS drug delivery platforms. The FDA clearance of MRgFUS for essential tremor thalamotomy in 2016 has established the regulatory foundation for expanded CNS indications.
Six Distinct FUS Approaches Across the CNS Drug Delivery Pipeline
Retrieved results spanning 80+ patent and literature records document six mechanistically distinct FUS modalities, ranging from FDA-cleared thermal ablation to preclinical gene therapy platforms.
Low-Intensity Pulsed FUS + Microbubble BBB Opening (FUS-BBBO)
The mechanism relies on acoustic cavitation — specifically stable oscillation of systemically administered microbubbles within brain capillaries — generating mechanical stress on endothelial tight junctions and transiently increasing BBB permeability without thermal ablation. Appears in more than 40 of the 80+ retrieved records. First-in-human clinical trials are referenced explicitly, including a dose-escalation Phase I trial using the NaviFUS device in recurrent GBM patients.
MI 0.3–0.8 · 0.22–1.68 MHzMR-Guided Focused Ultrasound (MRgFUS) — High-Intensity Thermal Ablation
At high intensities, FUS produces coagulative necrosis via thermal deposition in precisely targeted brain volumes. FDA clearance was received for unilateral thalamotomy in essential tremor (2016). Integration with real-time MRI thermometry enables precise temperature monitoring. Under clinical investigation for GBM, Parkinson's disease, and psychiatric conditions.
FDA Cleared 2016Nanoparticle-Mediated FUS Drug Delivery
Extensive preclinical work couples FUS-BBBO with systemically administered nanoparticle systems to exploit BBB opening for targeted payload delivery. Platforms include liposomes, hollow mesoporous organosilica nanoparticles (HMONs), poly(2-ethyl-butyl cyanoacrylate) NP-stabilized microbubbles, PEGylated brain-penetrating nanoparticles, and cationic NPs carrying siRNA. In vivo FUS increased in vitro BBB permeation by up to 9.5-fold for 3- and 15-nm gold nanoparticles.
9.5× permeation increase (3–15 nm AuNPs)Gene Therapy via FUS-BBBO
Delivery of viral vectors (AAV2, AAV2/1, rAAV) and non-viral gene-bearing nanoparticles to the CNS through FUS-induced BBB opening. Key molecular cargo includes GFP reporter genes, LacZ, GDNF, and oncogene-targeting siRNA. Retrovirus-loaded GDNF microbubbles combined with FUS demonstrated significantly increased GDNF expression and behavioral improvement in a rat PD model over 8 weeks.
AAV2 · rAAV · siRNA-NPsFUS Neuromodulation (Without BBB Opening)
A mechanistically distinct application of FUS at low intensities without microbubbles — direct modulation of neuronal activity through acoustic radiation force and membrane mechanosensitivity. Gas vesicles (GVs) are documented as nanoscale actuators for improving spatial precision of ultrasonic neuromodulation. Small cohort clinical studies demonstrate safe BBB opening in Alzheimer's disease, Parkinson's disease, and ALS patients.
Gas vesicle actuators · AD, PD, ALSImplantable Ultrasound Systems (CarThera)
An implantable, MR-compatible ultrasound device developed by CarThera (Lyon, France) for repeated BBB disruption in recurrent GBM patients receiving IV carboplatin, representing a distinct device-delivery paradigm from transcranial FUS. Initial Phase I/IIa safety and feasibility observations have been reported.
Implantable · IV Carboplatin · GBMKey Data Points from the FUS Drug Delivery Literature
All values sourced directly from patent and literature records retrieved via PatSnap Eureka. No estimates or fabricated data.
FUS-BBBO Drug Accumulation Enhancement (Fold-Increase)
FUS BBB opening increased Evans blue accumulation 3.8× in normal brain and 2.1× in tumor tissue in a 9L glioma rat model, with 9.5× in vitro permeation for small gold nanoparticles.
FUS Modality Distribution Across 80+ Retrieved Records
FUS-BBBO with microbubbles dominates the retrieved dataset, appearing in more than 40 of 80+ records, reflecting its status as the primary translational platform.
Seven Clinical Signals Distinguishing This Pipeline
Retrieved results contain multiple explicit clinical signals, distinguishing this dataset from purely preclinical fields and confirming active human translation.
FDA Clearance — MRgFUS Thermal Ablation (2016)
FDA clearance of MRgFUS for unilateral thalamotomy in essential tremor constitutes the regulatory anchor for expanded neuro-oncology and BBB opening indications, providing the hardware and safety precedent for ongoing GBM and neurodegenerative disease trials.
NaviFUS Phase I Trial — Recurrent GBM
A first-in-human, prospective, open-label, single-center, dose-escalation Phase I trial using the NaviFUS neuronavigation-guided FUS-MB system in recurrent GBM patients is explicitly described. Six patients were enrolled across three escalating dose cohorts (Chang Gung University, 2020).
CarThera Phase I/IIa — Implantable BBB Disruption
An implantable ultrasound device for repeated BBB disruption in recurrent GBM patients receiving IV carboplatin reached Phase I/IIa, with initial safety and feasibility observations reported by CarThera (Lyon, France, 2015).
Parkinson's Disease Putamen Targeting (Clinical)
A clinical trial using an ExAblate Neuro MRgFUS system operating at 220 kHz evaluated biweekly putamen BBB opening with Definity microbubble infusion and cavitation feedback control in Parkinson's patients (Krembil Research Institute, 2022).
Institutional Clustering Across North America, Asia, and Europe
Retrieved results are overwhelmingly literature-driven (academic papers), with a smaller but strategically significant patent cohort. The field exhibits strong institutional clustering. Columbia University is among the most prolific contributors, with multiple papers spanning primate BBB opening safety, neuronavigation-guided systems, MRI monitoring methods, real-time acoustic mapping, and neuroimmunomodulation across 2012–2023 — indicating sustained long-term research investment.
ETH Zurich is the dominant patent assignee in this dataset, with a family of patents (AU, CA, EP, US, WO) protecting a method for aggregation-then-uncaging FUS sequences applied to microbubble-loaded drug carriers below harmful cavitation thresholds. DCB-USA LLC holds an active European patent on neuronavigation-guided FUS systems, suggesting commercial IP positioning in the device guidance space.
Chang Gung Memorial Hospital / Chang Gung University (Taiwan) is a major Asian center for FUS-BBB clinical translation and is responsible for the NaviFUS clinical trial in recurrent GBM. CarThera (France) is a commercial entity at Phase I/IIa with an implantable BBB disruption device. Track competitive IP positioning across all these assignees using PatSnap Analytics.
For life sciences researchers exploring the CNS drug delivery space, PatSnap's life sciences platform provides deep patent landscape analysis across all therapeutic modalities. Explore customer case studies to see how R&D teams use patent intelligence to de-risk CNS pipeline decisions.
Convergent Strategies Documented in the 2020–2023 Literature
Retrieved results from 2020–2023 signal several convergent combination strategies and emerging technical directions that represent the frontier of the FUS drug delivery field.
Map emerging FUS combination approaches in your pipeline
PatSnap Eureka surfaces convergent strategies across 80+ FUS records from Columbia, ETH Zurich, Johns Hopkins, and more.
Focused Ultrasound Drug Delivery — Key Questions Answered
The BBB prevents passage of greater than 98% of systemically administered pharmaceutical agents due to tight junctions connecting adjacent endothelial cells, highly selective transporter systems, and low transcytotic activity.
Retrieved results cite mechanical indices typically between 0.3 and 0.8 and frequencies ranging from 0.22 MHz to 1.68 MHz for low-intensity pulsed FUS combined with microbubble-mediated BBB opening.
Yes. MRgFUS has received FDA clearance for unilateral thalamotomy in essential tremor (2016), constituting the regulatory anchor for expanded neuro-oncology and BBB opening indications.
A first-in-human, prospective, open-label, single-center, dose-escalation Phase I trial using the NaviFUS neuronavigation-guided FUS-MB system in recurrent GBM patients was conducted, with six patients enrolled across three escalating dose cohorts. CarThera also completed a Phase I/IIa trial using an implantable ultrasound device for repeated BBB disruption in recurrent GBM patients receiving IV carboplatin.
Preclinical evidence shows that FUS-BBB opening increased local accumulation of Evans blue dye by 3.8-fold in normal brain and 2.1-fold in tumor tissue in a 9L glioma rat model, with corresponding enhancement of TMZ delivery in cerebrospinal fluid.
FUSIN (focused ultrasound-mediated intranasal brain drug delivery technique) combines FUS with intranasal drug administration, exploiting the nose-to-brain pathway to bypass systemic exposure while using FUS to enhance focal transport at the targeted brain region. This approach minimizes off-target organ toxicity while maintaining regional specificity.
Still have questions? Let PatSnap Eureka search the FUS patent and literature database for you.
Ask PatSnap Eureka →Accelerate Your FUS Drug Delivery Pipeline with AI-Powered Patent Intelligence
Join 18,000+ innovators already using PatSnap Eureka to accelerate their R&D — search 80+ focused ultrasound records and track the full BBB opening pipeline in minutes.
References
- Optimization of the Ultrasound-Induced Blood-Brain Barrier Opening — Columbia University, 2012
- Ultrasound-mediated disruption of the blood tumor barrier for improved therapeutic delivery — West Virginia University, 2021
- Ultrasound-mediated delivery of brain-penetrating nanoparticles across the blood-tumor barrier — University of Virginia, 2015
- Treatment of Parkinson's disease using focused ultrasound with GDNF retrovirus-loaded microbubbles — Xinxiang Medical University, 2020
- Focused Ultrasound-Mediated Blood–Brain Barrier Opening Best Promotes Neuroimmunomodulation through Brain Macrophage Redistribution — Columbia University, 2023
- Focused Ultrasound-Induced Blood–Brain Barrier Opening to Enhance Temozolomide Delivery for Glioblastoma Treatment — National Sun Yat-sen University, 2013
- Blood-brain barrier disruption and delivery of irinotecan in a rat model using a clinical transcranial MRI-guided focused ultrasound system — Harvard Medical School, 2020
- Ultrasound-mediated blood-brain barrier opening enhances delivery of therapeutically relevant formats of a tau-specific antibody — University of Queensland, 2019
- Investigating the optimum size of nanoparticles for their delivery into the brain assisted by focused ultrasound-induced blood–brain barrier opening — University of Tokyo, 2020
- Feasibility and safety of focused ultrasound-enabled liquid biopsy in the brain of a porcine model — Washington University in St. Louis, 2020
- Neuronavigation-guided focused ultrasound (NaviFUS) for transcranial blood-brain barrier opening in recurrent glioblastoma patients: clinical trial protocol — Chang Gung University, 2020
- Temporary disruption of the blood-brain barrier using an implantable ultrasound system for recurrent glioblastoma patients under IV carboplatin chemotherapy — CarThera, 2015
- Focused Ultrasound-mediated Drug Delivery in Humans – a Path Towards Translation in Neurodegenerative Diseases — University of Queensland, 2022
- Cavitation Feedback Control of Focused Ultrasound Blood-Brain Barrier Opening for Drug Delivery in Patients with Parkinson's Disease — Krembil Research Institute, 2022
- From Focused Ultrasound Tumor Ablation to Brain Blood Barrier Opening for High Grade Glioma: A Systematic Review — INSERM, 2021
- Focused ultrasound-mediated intranasal brain drug delivery technique (FUSIN) — Washington University School of Medicine, 2021
- Magnetic Resonance-Guided Focused Ultrasound: Current Status and Future Perspectives in Thermal Ablation and Blood-Brain Barrier Opening — University of Toronto, 2019
- National Institutes of Health (NIH) — Neurological Disorders Research
- World Health Organization (WHO) — Neurological Disorders Global Burden
- U.S. Food and Drug Administration (FDA) — MRgFUS Device Clearance
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only.
PatSnap Eureka searches patents and research to answer instantly.